Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in
treating ocular hypertension and open-angle glaucoma compared to latanoprost. Hypothesis: The
ocular hypotensive efficacy of each dose of AR-12286 ophthalmic solution will not be
different from that of an active control.